Q-omics provides the consensus-scored NAXD profile across patient tissues and cancer cell-line models. NAXD expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NAXD is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, NAXD protein abundance shows 30,135 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, KICH, and PDAC as cancer lineages where NAXD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAXD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAXD survival associations across molecular data types. NAXD RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAXD RNA expression–survival associations across cancer types. High NAXD expression shows unfavorable associations in UVM, LAML, CESC and ACC, but favorable associations in UCEC and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for NAXD RNA expression.
This table summarizes NAXD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAXD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAXD shows lower tumor expression in KICH, KIRC, THCA and KIRP and higher tumor expression in COAD and HNSC. The KICH box plot shows higher NAXD RNA expression in normal versus tumor tissue (log2 FC = −1.172, t-test p < 0.001).
This table shows molecular features associated with NAXD in patient tissues and cancer cell lines. In patient samples, NAXD shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAXD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
